Nascent Biotech has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. The summarized Phase I data can be seen here in the poster presented at ASCO 2023. Nascent Biotech therapeutic antibody Pritumumab is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
